341 related articles for article (PubMed ID: 15753401)
1. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
[TBL] [Abstract][Full Text] [Related]
3. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz J; Brück J; Lenz J; Knop J; Tüting T
Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
Mendiratta SK; Thai G; Eslahi NK; Thull NM; Matar M; Bronte V; Pericle F
Cancer Res; 2001 Feb; 61(3):859-63. PubMed ID: 11221870
[TBL] [Abstract][Full Text] [Related]
6. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
7. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
8. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
10. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
Jorritsma A; Bins AD; Schumacher TN; Haanen JB
Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
[TBL] [Abstract][Full Text] [Related]
11. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma.
O I; Blaszczyk-Thurin M; Shen CT; Ertl HC
Cancer Gene Ther; 2003 Sep; 10(9):678-88. PubMed ID: 12944987
[TBL] [Abstract][Full Text] [Related]
12. 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity.
Kim JH; Chen J; Majumder N; Lin H; Falo LD; You Z
Gene Ther; 2005 Oct; 12(20):1517-25. PubMed ID: 16052205
[TBL] [Abstract][Full Text] [Related]
13. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
16. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U
Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366
[TBL] [Abstract][Full Text] [Related]
17. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
18. A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis.
Qu P; Ma JH; Zhang XM; Huang XJ; Yang XW; Yan-Fang S
Indian J Exp Biol; 2010 May; 48(5):436-43. PubMed ID: 20795360
[TBL] [Abstract][Full Text] [Related]
19. A simple method to cure established tumors by inflammatory killing of normal cells.
Daniels GA; Sanchez-Perez L; Diaz RM; Kottke T; Thompson J; Lai M; Gough M; Karim M; Bushell A; Chong H; Melcher A; Harrington K; Vile RG
Nat Biotechnol; 2004 Sep; 22(9):1125-32. PubMed ID: 15300260
[TBL] [Abstract][Full Text] [Related]
20. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
